News from AHA 2024: ATTRibute-CM-OLE; acoramidis; TTR

Daniel Judge at AHA

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
AHA 2024
Tirzepatide reduces HF events in patients with HFpEF and obesity
- Milton Packer, MD
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
AHA 2024
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
- Shawna Nesbitt, MD
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
AHA 2024
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
- Léna Rivard, MD